Solventum Corporation $SOLV Stock Sold by Equity Investment Corp

Equity Investment Corp lessened its holdings in shares of Solventum Corporation (NYSE:SOLV) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 867,554 shares of the company’s stock after selling 14,466 shares during the quarter. Equity Investment Corp’s holdings in Solventum were worth $76,475,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WINTON GROUP Ltd purchased a new stake in Solventum in the second quarter worth about $3,402,000. Squarepoint Ops LLC grew its holdings in shares of Solventum by 6,103.8% during the 2nd quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock worth $18,757,000 after acquiring an additional 239,209 shares during the period. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Solventum during the 2nd quarter worth approximately $150,066,000. Lone Peak Global Investors LLC grew its holdings in shares of Solventum by 38.5% during the 2nd quarter. Lone Peak Global Investors LLC now owns 433,128 shares of the company’s stock worth $33,416,000 after acquiring an additional 120,352 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Solventum by 16,656.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock worth $42,570,000 after acquiring an additional 480,048 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SOLV. Stifel Nicolaus lifted their price target on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Saturday. KeyCorp increased their price objective on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Weiss Ratings lowered Solventum from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Monday. Finally, BTIG Research restated a “buy” rating on shares of Solventum in a report on Friday. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Solventum currently has an average rating of “Moderate Buy” and an average price target of $90.27.

Solventum Stock Performance

Shares of SOLV stock opened at $90.09 on Wednesday. The company has a market capitalization of $15.29 billion, a price-to-earnings ratio of 12.83, a price-to-earnings-growth ratio of 1.29 and a beta of 0.69. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.72 and a current ratio of 1.03. Solventum Corporation has a one year low of $62.38 and a one year high of $94.16. The company’s 50-day moving average is $87.71 and its 200 day moving average is $78.80.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11. The business had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.50 earnings per share. Sell-side analysts expect that Solventum Corporation will post 7.26 EPS for the current fiscal year.

Solventum Profile

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024. The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.